Publication: Young coconut juice, a potential therapeutic agent that could significantly reduce some pathologies associated with Alzheimer's disease: Novel findings
1
Issued Date
2011-03-14
Resource Type
ISSN
14752662
00071145
00071145
Other identifier(s)
2-s2.0-79953137074
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
British Journal of Nutrition. Vol.105, No.5 (2011), 738-746
Suggested Citation
Nisaudah Radenahmad, Farid Saleh, Kitja Sawangjaroen, Uraporn Vongvatcharanon, Patchara Subhadhirasakul, Wilart Rundorn, Boonsirm Withyachumnarnkul, James R. Connor Young coconut juice, a potential therapeutic agent that could significantly reduce some pathologies associated with Alzheimer's disease: Novel findings. British Journal of Nutrition. Vol.105, No.5 (2011), 738-746. doi:10.1017/S0007114510004241 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/12589
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Young coconut juice, a potential therapeutic agent that could significantly reduce some pathologies associated with Alzheimer's disease: Novel findings
Abstract
Brains from ovariectomised (ovx) rats can display features similar to those observed in menopausal women with Alzheimer's disease (AD), and oestrogen seems to play a key role. Preliminary studies on young coconut juice (YCJ) have reported the presence of oestrogen-like components in it. The aim of the study was to investigate the effects of YCJ on the AD pathological changes in the brains of ovx rats. Rat groups included sham-operated, ovx, ovx+oestradiol benzoate (EB) and ovx+YCJ. Brain sections (4m) were taken and wer e immunostained with -amyloid (A) 1-42, glial fibrillary acidic protein (GFAP) (an intermediate neurofilament of astrocytes) and Tau-1 antibodies. A 1-42, GFAP and Tau-1 are considered as reliable biomarkers of amyloidosis, astrogliosis and tauopathy (neurofibrillary tangles), respectively, which in turn are characteristic features associated with AD. The serum oestradiol (E2) level was measured using a chemiluminescent immunoassay technique. YCJ restored the serum E2 to levels significantly (P < ·001) higher than that of the ovx group, and even that of the sham group. A deposition was significantly (P < ·0001) reduced in the cerebral cortex of the YCJ group, as compared with the ovx group and with the sham and ovx+EB groups (P < ·01). A similar trend was observed in relation to GFAP expression in the cerebral cortex and to Tau-1 expression in the hippocampus. This is a novel study demonstrating that YCJ could have positive future implications in the prevention and treatment of AD in menopausal women. © The Authors 2010.